Lesson of the Week

Cholestasis secondary to anabolic steroid use in young men

BMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e468 (Published 2 February 2012)
Cite this as: BMJ 2012;344:e468

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ahmed M Elsharkawy, locum consultant gastroenterologist/hepatologist 1,
  2. Stuart McPherson, consultant hepatologist12,
  3. Steven Masson, consultant hepatologist12,
  4. Alastair D Burt, professor of histopathology2,
  5. Robert T Dawson, general practitioner3,
  6. Mark Hudson, consultant hepatologist1, honorary senior lecturer2
  1. 1Liver Unit, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
  2. 2Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne
  3. 3Medical Centre, The Grove, Rowlands Gill NE39 1PW, UK
  1. Correspondence to: A M Elsharkawy ahmede{at}doctors.org.uk
  • Accepted 21 November 2011

Ask about use of anabolic steroids in young men with unexplained cholestasis to prevent progressive liver injury

In the face of increasing societal pressure to achieve bodily perfection, young men in particular sometimes turn to anabolic steroids to help them achieve the body they want. The health consequences of this choice are often overlooked. We describe two cases of severe cholestatic liver disease in young men who had taken anabolic steroids with the aim of enhancing their body image.

Case reports

Case 1

A 32 year old man presented with a seven day history of nausea, vomiting, and jaundice associated with severe itching. He had no medical history of note and had not taken any prescribed medications for several years. He did not drink alcohol regularly and denied having used recreational drugs, although he eventually admitted having taken 5 mg a day of methandrostenolone for the first time in the previous two months. He stated that he took the drug to enhance his body image.

Blood tests on admission showed bilirubin 651 µmol/L (normal range 0 to 19), alanine aminotranferase 76 IU/L (0 to 45), alkaline phosphatase 262 IU/L (35 to 120), and international normalised ratio 1.3. An extended liver screen (including serological testing for hepatitis A, B, C, and E as well as for cytomegalovirus and Epstein-Barr virus, full autoantibody profile, and markers of metabolic liver diseases), abdominal ultrasonography, and magnetic resonance cholangiopancreatography failed to identify any alternative causes. Cholestasis induced by anabolic steroids was diagnosed clinically (after his history of use of anabolic steroids had been ascertained). He was initially treated with ursodeoxycholic acid and observed. He became severely hypertensive on day 2, needing treatment with amlodipine. A liver biopsy on day 4 (performed because of a progressive rise in bilirubin concentration) showed bland cholestasis, in …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL